CN101102757A - 治疗多囊性肾疾病的方法 - Google Patents

治疗多囊性肾疾病的方法 Download PDF

Info

Publication number
CN101102757A
CN101102757A CNA2005800338888A CN200580033888A CN101102757A CN 101102757 A CN101102757 A CN 101102757A CN A2005800338888 A CNA2005800338888 A CN A2005800338888A CN 200580033888 A CN200580033888 A CN 200580033888A CN 101102757 A CN101102757 A CN 101102757A
Authority
CN
China
Prior art keywords
carbon atoms
group
alkyl
carbon
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800338888A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·弗罗斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN101102757A publication Critical patent/CN101102757A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2005800338888A 2004-10-08 2005-10-07 治疗多囊性肾疾病的方法 Pending CN101102757A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61698104P 2004-10-08 2004-10-08
US60/616,981 2004-10-08

Publications (1)

Publication Number Publication Date
CN101102757A true CN101102757A (zh) 2008-01-09

Family

ID=36013658

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800338888A Pending CN101102757A (zh) 2004-10-08 2005-10-07 治疗多囊性肾疾病的方法

Country Status (12)

Country Link
US (1) US20060079515A1 (enExample)
EP (1) EP1796727A2 (enExample)
JP (1) JP2008515913A (enExample)
CN (1) CN101102757A (enExample)
AR (1) AR052221A1 (enExample)
AU (1) AU2005294258A1 (enExample)
BR (1) BRPI0516533A (enExample)
CA (1) CA2580864A1 (enExample)
MX (1) MX2007004001A (enExample)
PE (1) PE20060681A1 (enExample)
TW (1) TW200616612A (enExample)
WO (1) WO2006042100A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200706804B (en) 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
JP2010523579A (ja) 2007-04-02 2010-07-15 インスティテュート フォア ワンワールド ヘルス Ｃｆｔｒ阻害剤化合物およびそれらの使用
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20100099677A1 (en) * 2008-04-21 2010-04-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Thiazole Derivatives
WO2009131957A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
DK2310011T3 (da) 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
CA2730715C (en) 2008-08-04 2013-10-01 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
EP2341776A4 (en) * 2008-09-19 2012-05-30 Inst Oneworld Health COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING IMIDAZOL AND TRIAZOL DERIVATIVES
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
AU2011293315A1 (en) 2010-08-26 2013-03-14 Symphony Evolution, Inc. Use of a receptor-type kinase modulator for treating polycystic kidney disease
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
HK1217092A1 (zh) 2013-02-15 2016-12-23 Kala Pharmaceuticals, Inc. 治疗性化合物及其用途
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
NZ719185A (en) 2013-11-01 2017-11-24 Kala Pharmaceuticals Inc Crystalline forms of therapeutic compounds and uses thereof
CA3036340A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CA3036065A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2018048747A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
WO2003050090A1 (en) * 2001-11-27 2003-06-19 Wyeth Holdings Corporation 3-cyanoquinolines as inhibitors of egf-r and her2 kinases

Also Published As

Publication number Publication date
AR052221A1 (es) 2007-03-07
WO2006042100A3 (en) 2007-06-07
WO2006042100A2 (en) 2006-04-20
TW200616612A (en) 2006-06-01
EP1796727A2 (en) 2007-06-20
AU2005294258A1 (en) 2006-04-20
JP2008515913A (ja) 2008-05-15
CA2580864A1 (en) 2006-04-20
PE20060681A1 (es) 2006-08-28
BRPI0516533A (pt) 2008-09-09
MX2007004001A (es) 2007-05-11
US20060079515A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
CN101102757A (zh) 治疗多囊性肾疾病的方法
CA2401502A1 (en) Carboxylic acid derivatives as ip antagonists
KR102889174B1 (ko) 해수 (咳嗽) 의 치료를 위한 의약
EP1948176B1 (en) Diaryl ureas for treating pulmonary hypertension
JP2022535406A (ja) Ｐｒｍｔ５阻害剤を使用した癌の治療法
JP2010528980A (ja) 精神障害を治療するためのｐ３８キナーゼ阻害剤の使用
US6197796B1 (en) Anticancer composition comprising a diaminotrifluoromethylpyridine derivative
AU2007234917B2 (en) Renin inhibitors for the treatment of hypertension
RU2294198C2 (ru) Производные арил(или гетероарил)азолилкарбинола для лечения респираторных заболеваний
US5476858A (en) Use of carbostyril to increase somatostatin or for inhibiting decrease of somatostatin to treat diseases related thereto
EA010868B1 (ru) Применение производных бицикло[2.2.1]гептана для приготовления нейропротекторных фармацевтических композиций
JPWO2023147418A5 (enExample)
JPH10120592A (ja) メニエール病乃至メニエール症候群治療剤
WO2024036274A1 (en) Metap2 inhibitors for the treatment of pulmonary fibrosis
JP2003267871A (ja) 放射線障害予防剤
CN101355941A (zh) 治疗肺动脉高血压的二芳基脲
JPH08157366A (ja) 脳浮腫治療剤
CN101355944A (zh) 治疗肺动脉高血压的二芳基脲
JPH06509587A (ja) ソマトスタチン増加用またはソマトスタチン低下抑制用薬剤
JPH09118620A (ja) 放射線肺障害予防・治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080109